Physiomics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Physiomics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-27.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-27.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

It's Unlikely That Shareholders Will Increase Physiomics Plc's (LON:PYC) Compensation By Much This Year

Nov 15

Here's Why We Think Physiomics Plc's (LON:PYC) CEO Compensation Looks Fair

Nov 17

Here's Why Shareholders Will Not Be Complaining About Physiomics Plc's (LON:PYC) CEO Pay Packet

Nov 16

What Can We Conclude About Physiomics' (LON:PYC) CEO Pay?

Feb 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PYC şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PYC şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Physiomics Piyasaya Karşı Temettü Getirisi

PYC temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PYC)	n/a
Pazarın Alt %25'i (GB)	2.2%
Pazarın En İyi %25'i (GB)	6.0%
Sektör Ortalaması (Life Sciences)	0.7%
Analist tahmini (PYC) (3 yıla kadar)	n/a

Önemli Temettü: PYC şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PYC şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PYC şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PYC herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Physiomics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Physiomics plc Appoints Dr. Mark Davies as Head of Quantitative Pharmacology and Data Science

Physiomics Plc, Annual General Meeting, Nov 19, 2024

Full year 2024 earnings: Revenues miss analyst expectations

New minor risk - Financial data availability

New major risk - Shareholder dilution

Dr. Christophe Chassagnole Step Down as Director and as Chief Scientific Officer of Physiomics plc

Physiomics Plc Increases Revenue Expectation for the Year 2025

First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.002 loss in 1H 2023)

Physiomics Plc to Report First Half, 2024 Results on Mar 07, 2024

New minor risk - Shareholder dilution

Less than half of directors are independent

Physiomics plc Announces Chief Executive Officer Changes

It's Unlikely That Shareholders Will Increase Physiomics Plc's (LON:PYC) Compensation By Much This Year

Physiomics Plc, Annual General Meeting, Nov 21, 2023

Physiomics Plc Appoints Dr Venkata Putcha, as Head of Biostatistics

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Financial data availability

New minor risk - Financial data availability

Physiomics plc Appoints Dr. Peter Sargent as Chief Operating Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2022)

Physiomics plc Announces Change of Job Title of Dr. Christophe Chassagnole from Chief Operating Officer to Chief Scientific Officer

Physiomics Plc Announces Successful Completion of its PARTNER Study

Here's Why We Think Physiomics Plc's (LON:PYC) CEO Compensation Looks Fair

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Physiomics Plc, Annual General Meeting, Nov 22, 2022

Third quarter 2022 earnings released: UK£0.001 loss per share (vs UK£0.001 loss in 3Q 2021)

Physiomics Plc to Report Fiscal Year 2022 Results on Sep 29, 2022

Physiomics Plc Appoints Shalabh Kumar as Independent Non-Executive Director

Less than half of directors are independent

Physiomics plc Announces Board Changes, Effective April 1, 2022

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Physiomics Plc to Report First Half, 2022 Results on Mar 07, 2022

Physiomics plc Announces Board Changes

Here's Why Shareholders Will Not Be Complaining About Physiomics Plc's (LON:PYC) CEO Pay Packet

Full year 2021 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in FY 2020)

Physiomics plc Announces Earnings Guidance for the Year Ending June 30, 2021

First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.001 loss in 1H 2020)

What Can We Conclude About Physiomics' (LON:PYC) CEO Pay?

TRHC’s DoseMeRx Partners with Physiomics to Provide Precision Dosing for Oncology Medications

Physiomics Plc Announces Approval of NIHR-funded PARTNER Study

Full year earnings released - UK£0.00087 loss per share

Annual earnings released: Earnings beat expectations, revenue disappoints

Physiomics plc Receives Award from Bicycle Therapeutics plc and Merck KGaA to Further Contracts of Undisclosed Value for Projects

Full year earnings released - UK£0.00087 loss per share

Physiomics Plc to Report Fiscal Year 2020 Results on Sep 30, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin